GSK finds a buyer willing to take its Paris R&D site off its hands — for a hefty fee
After shopping the François Hyafil Research Centre near Paris for the past year, GlaxoSmithKline says it finally has a buyer — and the deal will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
